HEALTH OF WOMAN. 2020.9-10(155-156): 114-118; doi 10.15574/HW.2020.155-156.114
Potapova L. V., Shcherbina I. N.
Kharkiv National Medical University

The development of urogenital disorders in perimenopause is characterized by the manifestation of atrophic and dystrophic processes in the structures of the genitourinary tract.
The objective: improving the effectiveness of treatment of women with urogenital disorders in perimenopause by studying the effect of local application of liquid vaginal suppositories Vaginal-Panten.
Materials and methods. We examined 176 women with urogenital disorders in perimenopausal period, whose average age was 52.2±4.8 years. In group I – 86 (48.8%) patients received traditional treatment. Group II included 90 (51.1%) patients who, in order to eliminate the symptoms of bacterial vaginosis due to individual intolerance to local HRT, were prescribed Vaginal-Panten liquid suppositories intravaginally to restore the vaginal microbiota. The control group included 52 women with the physiological course of the perimenopausal period.
Results. As a result of the treatment, there was a decrease in vaginal dryness and itching in 87.7% of cases, no vaginal burning sensation in 74.4% of cases, normalization of the clinical analysis of urine samples, a significant decrease in nocturia by 3 times, a positive cough test by 2 times and pollakiuria by 2.5 times (p<0.05).
Conclusion. Vaginal suppositories “Vaginal-Panten” can be successfully used in the treatment of urogenital disorders in perimenopause, which is especially important for women with contraindications to the use of synthetic estrogen-containing drugs.
Keywords: urogenital disorders, perimenopausal period, treatment, Vaginal suppositories “Vaginal-Panten”.

REFERENCES

1. Alvisi S, Gava G, Orsili I, Giacomelli G, Baldassarre M, Seracchioli R & Meriggiola MC. 2019. Vaginal health in menopausal women. Medicina (Lithuania). 55(10). https://doi.org/10.3390/medicina55100615; PMid:31547180 PMCid:PMC6843679

2. Baber RJ, Panay N, Fenton A and the IMS Writing Group. 2016. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric. 19(2):109-50. https://doi.org/10.3109/13697137.2015.1129166; PMid:26872610

3. Brotman RM, Shardell MD, Gajer P, Fadrosh D, Chang K, Silver MI, Gravitt PE. 2018. Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy. Menopause 25(11):1321-1330. https://doi.org/10.1097/GME.0b013e3182a4690b; PMid:24080849 PMCid:PMC3994184

4. Cagnacci A, Venier M, Xholli A, Paglietti C & Caruso S. 2020. Female sexuality and vaginal health across the menopausal age. Menopause 27(1):14-19. https://doi.org/10.1097/GME.0000000000001427; PMid:31738734

5. Cagnacci A, Xholli A, Sclauzero M, Venier M, Palma F & Gambacciani M. 2019. Vaginal atrophy across the menopausal age: Results from the ANGEL study. Climacteric. 22(1):85-89. https://doi.org/10.1080/13697137.2018.1529748; PMid:30601037

6. Chernova NI, Arutyunyan E. 2018. Current aspects of treatment in patients with dystrophy and atrophy of the intimate area. What is new? Rossiyskiy vestnik akushera-ginekologa = Russian Bulletin of Obstetrician-Gynecologist. 18(3):95-98. (In Russ.) https://doi.org/10.17116/rosakush201818295-98

7. Dobrokhotova YuE, Ilyina IYu, Venediktova MG, Morozova KV, Suvorova VA. 2018. Local nonhormonal therapy in patients with genitourinary menopausal syndrome. Rossiyskiy vestnik akushera-ginekologa = Russian Bulletin of Obstetrician-Gynecologist. 18(3):88-94. (In Russ.). https://doi.org/10.17116/rosakush201818288-94

8. Dijaković A. 2012. Urogenital atrophy (UGA) incontinence as an estrogenic deficit result in perimenopause and postmenopause. Urogenitalna atrofija (UGA) / inkontinencija kao posljedica estrogenog deficita u peri i postmenopauzi. Medica Jadertina 42(1-2):51-54.

9. Fait T. 2019. Menopause hormone therapy: Latest developments and clinical practice. Drugs in Context. 8. https://doi.org/10.7573/dic.212551; PMid:30636965 PMCid:PMC6317580

10. Gao M, Goodman A, Mishra G & Koupil I. 2019. Associations of birth characteristics with perimenopausal disorders: A prospective cohort study. Journal of Developmental Origins of Health and Disease. 10(2):246-252. https://doi.org/10.1017/S204017441800065X; PMid:30296955

11. Gradison M. 2009. Menstrual, urogynecological and vasomotor changes in perimenopause and menopause. Handbook of women's health, second edition:137-144. https://doi.org/10.1017/CBO9780511642111.011

12. Hodges AL, Holland AC, Dehn B & Pace DT. 2018. Diagnosis and treatment of genitourinary syndrome of menopause. Nursing for Women's Health. 22(5):423-430. https://doi.org/10.1016/j.nwh.2018.07.005; PMid:30170002

13. Hope ME, Farmer L, Mcallister KF & Cumming GP. 2010. Vaginismus in peri- and postmenopausal women: A pragmatic approach for general practitioners and gynaecologists. Menopause International. 16(2):68-73. https://doi.org/10.1258/mi.2010.010016; PMid:20729498

14. Nappi RE, Di Carlo C, Becorpi AM, Gambacciani M, De Seta F, Ribaldone R, Paoletti AM. 2020. The effect of vulvovaginal atrophy on women's quality of life from an italian cohort of the EVES study. Journal of Obstetrics and Gynaecology. 40(4):512-519. https://doi.org/10.1080/01443615.2019.1621824; PMid:31496326

15. O'Neill S & Eden J. 2017. The pathophysiology of menopausal symptoms. Obstetrics, Gynaecology and Reproductive Medicine. 27(10):303-310. https://doi.org/10.1016/j.ogrm.2017.07.002

16. Palacios S, Combalia J, Emsellem C, Gaslain Y & Khorsandi D. 2020. Therapies for the management of genitourinary syndrome of menopause. Post Reproductive Health. 26(1):32-42. https://doi.org/10.1177/2053369119866341; PMid:31387514

17. Palacios S, Hidalgo MJC, González SP, Manubens M & Sánchez-Borrego R. 2019. Genitourinary syndrome of menopause: Recommendations from the spanish society of obstetrics and gynecology. Sуndrome genitourinario de la menopausia: Recomendaciones de la sociedad espaсola de ginecología y obstetrician. Progresos De Obstetricia y Ginecologia. 62(2):141-148. doi:10.20960/j.pog.00182

18. Palacios S, Nappi RE, Bruyniks N, Particco M & Panay N. 2018. The european vulvovaginal epidemiological survey (EVES): Prevalence, symptoms and impact of vulvovaginal atrophy of menopause. Climacteric. 21(3):286-291. https://doi.org/10.1080/13697137.2018.1446930; PMid:29553288

19. Santoro N, Epperson CN & Mathews SB. 2015. Menopausal symptoms and their management. Endocrinology and Metabolism Clinics of North America. 44(3):497-515. https://doi.org/10.1016/j.ecl.2015.05.001; PMid:26316239 PMCid:PMC4890704

20. Sinha A, Ewies AA. 2013. Non-hormonal topical treatment of vulvovaginal atrophy: an up-todate overview. Climacteric. 16(3):305-312. https://doi.org/10.3109/13697137.2012.756466; PMid:23215675

21. Smetnik VP ed. Estrogeny. Prakticheskaya meditsin =. Estrogens. Practical medicine. 2012:128-133. (In Russ.) Available at: https://search.rsl.ru/ru/record/01005373152

22. Smetnik VP, Yureneva SV, Ermakova EI, Glazunova AV. 2015. Genitourinary menopausal syndrome. Diagnostics and treatment (draft clinical protocol). Climacterium [Klimakteriy]. (1):1-17. (In Russ.) Available at: https://docplayer.ru/109313713-V-nomere-genitourinarnyy-menopauzalnyy-sindrom-ekspertnoemnenie. html

23. Sukhikh GT, Smetnik VP, Yureneva SV, Ermakova EI, Chernukha GE, Yakushevskaya OV. 2016. Menopause and women's climacteric condition. Clinical recommendations. (In Russ.) Available at https://medi.ru/klinicheskie-rekomendatsii/menopauza-i-klimaktericheskoe-sostoyanie-u-zhenschiny_14063.

24. Stika CS. 2010. Atrophic vaginitis. Dermatologic Therapy. 23(5):514-522. https://doi.org/10.1111/j.1529-8019.2010.01354.x; PMid:20868405

25. The North American Menopause Society. 2013. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 20(9):888-902. https://doi.org/10.1097/GME.0b013e3182a122c2; PMid:23985562

26. The 2017 hormone therapy position statement of The North American Menopause Society NAMS. Menopause: The Journal of The North American Menopause Society. 2017. 24(7):728-753. Available at: https://www.menopause.org/docs/default-source/2017/nams-2017-hormonetherapy-position-statement.pdf. https://doi.org/10.1097/GME.0000000000000921; PMid:28650869

27. Yefimenko OО. 2020. Menopause. A problem that is not out of date: Specialist comment and updated data from the national consensus on the management of patients in menopause. Менопауза. проблема, що не втрачає актуальності: Коментарій фахівця та оновлені дані «Національного консенсусу щодо ведення пацієнток у клімактерії». Reproductive Endocrinology (51):72-88. https://doi.org/10.18370/2309-4117.2020.51.72-88

28. Yureneva SV, Ermakova EI, Glazunova AV. 2016. Genitourinary syndrome of menopause in periand postmenopausal patients: Diagnosis and therapy (short clinical guidelines). Akusherstvo I ginekologiya = Obstetrics and Gynecology (5):138-144. (In Russ.). https://doi.org/10.18565/aig.2016.5.138-144

29. Vdovychenko YP, Yefimenko OО, Pedachenko NY & Iatsyna OI. 2019. Differentiated approach to the treatment of genitourinary syndrome in perimenopausal women. Reproductive Endocrinology (46):8-18. https://doi.org/10.18370/2309-4117.2019.46.8-18